洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

【ChiCTR2200056193】Hiwa omer: please submit the approval letter of IRB

基本信息
登记号

ChiCTR2200056193

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2022-02-01

临床申请受理号

/

靶点

/

适应症

N/A

试验通俗题目

Hiwa omer: please submit the approval letter of IRB

试验专业题目

Sonographic Measurement of Splenic Size and its Correlation with Body Parameters in Kurdish Population

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

联系人通讯地址
临床试验信息
试验目的

This study aims to establish reference value of splenic dimensions, volume and its correlation to the different body parameters in Kurdish population

试验分类
试验类型

连续入组

试验分期

其它

随机化

N/A

盲法

N/A

试验项目经费来源

All funding was covered by authors.

试验范围

/

目标入组人数

300

实际入组人数

/

第一例入组时间

2020-08-07

试验终止时间

2021-03-05

是否属于一致性

/

入选标准

Normal healthy Kurdish adult male and female population in Sulaimani region who had normal complete blood count (CBC);

排除标准

Subjects in this study will fill a short-standardized interview questionnaire to exclude any previous or current conditions that might involve the size of the spleen & exclusion criteria were include: 1. Subjects with age younger than 20 years. 2. Clinical or laboratory evidence of infection or jaundice either at the time of the examination or within at least 6 weeks prior to the examination) 3. History of Rheumatoid disease 4. Anemia or haemoglobinopathies (thalassemia and sickle cell anemia). 5. Subjects with Hx of lymphoproliferative disorders or Myeloproliferative neoplasm 6. Subjects in whom the entire length of the spleen could not be properly documented by US or sonographically detectable focal spleen lesions. 7. History of splenic trauma& or those with partial splenectomy. 8. Liver diseases (cirrhosis or portal hypertension). 9. Gravid women. 10. Non-Kurdish races.;

研究者信息
研究负责人姓名
试验机构

medical school, Faculty of Medical Science, University of Sulaimani

研究负责人电话
研究负责人邮箱
研究负责人邮编

/

联系人通讯地址
<END>

medical school, Faculty of Medical Science, University of Sulaimani的其他临床试验

最新临床资讯

对摩熵医药数据库感兴趣,可以免费体验产品

同适应症药物临床试验